Weekly Investment Analysts’ Ratings Changes for KemPharm (KMPH)

Several brokerages have updated their recommendations and price targets on shares of KemPharm (NASDAQ: KMPH) in the last few weeks:

  • 3/14/2017 – KemPharm was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.75 price target on the stock. According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
  • 3/12/2017 – KemPharm was given a new $7.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 3/11/2017 – KemPharm had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.
  • 3/11/2017 – KemPharm was given a new $13.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 2/7/2017 – KemPharm was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

KemPharm Inc (NASDAQ:KMPH) opened at 4.225 on Tuesday. The company’s market cap is $61.88 million. KemPharm Inc has a one year low of $2.90 and a one year high of $19.75. The stock has a 50 day moving average of $3.83 and a 200 day moving average of $3.91.

KemPharm (NASDAQ:KMPH) last issued its earnings results on Thursday, March 9th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.02. On average, analysts anticipate that KemPharm Inc will post ($2.53) earnings per share for the current fiscal year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

5 Day Chart for NASDAQ:KMPH

Receive News & Ratings for KemPharm Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brazil Looks to Calm Fears Over Export and Sale of Meat
Brazil Looks to Calm Fears Over Export and Sale of Meat
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Oil Prices Drop to Low of Three Months on Rig Count
Oil Prices Drop to Low of Three Months on Rig Count
Shares of Staples Fall After Earnings Come Up Short
Shares of Staples Fall After Earnings Come Up Short
Trump Tweet Sends Pharmaceutical Stocks Tumbling
Trump Tweet Sends Pharmaceutical Stocks Tumbling


Leave a Reply

© 2006-2017 Ticker Report. Google+.